Table 1 Clinical and laboratory characteristics of all patients and according RLS presence
From: Restless legs syndrome and quality of sleep in patients with glomerulopathy
All glomerulopathy patients (n = 99) | Glomerulopathy patients with RLS (n = 18) | Glomerulopathy patients with no RLS (n = 81) | p | |
|---|---|---|---|---|
Age (years) | 36.2±11.8 | 34.4±9.1 | 36.5±14.8 | 0.359 |
Gender (M/F) | 46/53 | |||
Renal biopsy diagnosis | ||||
FSGS/ML | ||||
MN | 53 | 9/18 | 44/81 | 0.417 |
IgAN | 29 | 5/18 | 24/81 | |
MPGN | 9 | 2/18 | 7/81 | |
8 | 2/18 | 6/81 | ||
Disease duration (months) | 33.6±26.0 | 52±34 | 28±22 | 0.006 |
Arterial Hypertension | 40 | 7/18 | 33/81 | 0.853 |
Diabetes | 6 | 1/18 | 5/81 | 0.946 |
Current smoker | 7/99 | 2/18 | 5/81 | 0.614 |
Diagnosed Cardiovascular Disease | 4/99 | 1/18 | 3/81 | 0.563 |
Presence of edema | 31 | 7/18 | 24/81 | 0.443 |
Mean eGFR (mL/min/1.73 m2) | 61.2±29.4 | 64.1±27.6 | 60.9±30.5 | 0.872 |
CKD stage | ||||
stage 1 | 55 | 8/18 | 47/81 | 0.406 |
stage 2 | 24 | 7/18 | 17/81 | |
stage 3 | 16 | 2/18 | 14/81 | |
stage 4 | 04 | 1/18 | 3/81 | |
Statin therapy | 21/99 | 3/18 | 18/81 | 0.756 |
Antideperessant/neuroleptic therapy | 4/99 | 1/18 | 3/81 | 0.558 |
ACE inhibitor/AT1R blocker | 62 | 13/18 | 49/81 | 0.662 |
Steroid therapy | 43 | 10/18 | 33/81 | 0.485 |
Cyclosporine therapy | 19 | 3/18 | 16/81 | 0.802 |
Cyclophosphamide therapy | 03 | 0/18 | 3/81 | 1.0 |
Hemoglobin (g/dL) | 12.3±0.9 | 12.1±0.8 | 12.4±1.0 | 0.878 |
Serum Ferritin (μg/L) | 56.7 ± 31.0 | 48.6±29.1 | 58.8±33.4 | 0.683 |
Last serum albumin (g/dL) | 3.6±0.9 | 3.4±1.2 | 3.7±0.9 | 0.196 |
Last total cholesterol (mg/dL) | 221.2±98.9 | 239.0±84.3 | 218.6±46.4 | 0.258 |
Last triglycerides (mg/dL) | 146.2±58.3 | 164.1±69.0 | 142.2±42.4 | 0.389 |
Proteinuria at diagnosis (g/24 h/1.73 m2) | 8.6±3.8 | 9.1±4.1 | 8.5±3.7 | 0.395 |
Last proteinuria (g/24 h/1.73 m2) | 2.8±2.2 | 3.7±1.3 | 2.6±0.6 | 0.001 |
Remission | ||||
Total/Partial | 64 | 10/18 | 54/81 | 0.419 |
No | 35 | 8/18 | 27/81 | |
PSQI | 7.35±3.7 | 8.96±3.9 | 6.99±3.5 | 0.003 |